Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Bone and Mineral Research

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jbmr.1794PMID 23074140
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A rare cause of facial nerve palsy in children: hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review.

  2012cited by this paper
• Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover

  2011influential reference
• Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

  2011cited by this paper
• Glucocorticoids are not always deleterious for bone

  2010cited by this paper
• Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.

  2010cited by this paper
• Case 150: Van Buchem disease (hyperostosis corticalis generalisata).

  2009cited by this paper
• Sclerostin in Mineralized Matrices and van Buchem Disease

  2009influential reference
• Bone mineral density in sclerosteosis; affected individuals and gene carriers.

  2005cited by this paper
• Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

  2005cited by this paper
• Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

  2004cited by this paper
• The natural history of sclerosteosis

  2003cited by this paper
• Van Buchem disease: lifetime evolution of radioclinical features

  2003cited by this paper
• Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.

  2003cited by this paper
• Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

  2003cited by this paper
• Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

  2002cited by this paper
• A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

  2002cited by this paper
• Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

  2001cited by this paper
• Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

  2001cited by this paper
• [Van Buchem disease. Maxillofacial changes, diagnostic classification and general principles of treatment].

  1999cited by this paper
• Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21.

  1998cited by this paper
• Sclerosteosis: neurosurgical experience with 14 cases.

  1993cited by this paper
• Van Buchem disease: surgical treatment of the mandible.

  1988cited by this paper
• The syndromic status of sclerosteosis and van Buchem disease

  1984cited by this paper
• Two cases of Van Buchem's disease.

  1982cited by this paper
• Van Buchem disease.

  1977cited by this paper
• The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals.

  1976influential reference
• Van Buchem's disease (hyperostosis corticalis generalisata)

  1976cited by this paper
• Hyperostosis corticalis generalisata. Eight new cases.

  1971influential reference
• Van Buchem's disease (hyperostosis corticalis generalisata familiaris). A case report.

  1971cited by this paper
• Van Buchem's disease (hyperostosis corticalis generalisata familiaris). A case report.

  1968cited by this paper
• Hyperostosis corticalis generalisata: Report of seven cases

  1962cited by this paper
• Hyperostosis corticalis generalisata. Report of seven cases.

  1962cited by this paper
• Hyperostosis corticalis generalisata. Report of seven cases.

  1962cited by this paper
• An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris.

  1955cited by this paper

• Modeling rare genetic skeletal disorders with bone organoids: a narrative review.

  2026cites this paper
• Long-term clinical and bone mineral density changes of adult patients with sclerostin deficiency due to van Buchem disease: a follow-up study

  2025cites this paper
• Novel Loss of Function Variant in SOST From Chinese Family Results in Sclerosteosis 1

  2025cites this paper
• Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition.

  2025cites this paper
• Effects of Diode Laser Irradiation on Bone Formation in the Tibiae of Estrogen‐deficient Rats

  2025cites this paper
• Assessment of Reference Genes Stability in Cortical Bone of Obese and Diabetic Mice

  2024cites this paper
• Clinical meaning of high bone mineral density (Part I). Genetic diseases causing high bone mass

  2024cites this paper
• Sclerostin inhibits Protein kinase C inhibitor GÖ6976 induced osteogenic differentiation of dental follicle cells.

  2024cites this paper
• Serum level of sclerostin and vitamin D in children with epilepsy

  2024cites this paper
• Inhibition of both sclerostin and DKK1 results in novel skull findings in the rat and non-human primate that is not observed with inhibition of sclerostin alone.

  2023cites this paper
• Comprehensive analysis of epigenetics mechanisms in osteoporosis

  2023cites this paper
• Serum sclerostin levels in osteoporotic fracture patients

  2022cites this paper
• Sclerostin in the development of osteoarthritis: A mini review.

  2022cites this paper
• Zebrafish mutants reveal unexpected role of Lrp5 in osteoclast regulation

  2022cites this paper
• Wnt Pathway Extracellular Components and Their Essential Roles in Bone Homeostasis

  2022cites this paper
• Hereditary Metabolic Bone Diseases: A Review of Pathogenesis, Diagnosis and Management

  2022cites this paper
• Sclerostin Protects Against Vascular Calcification Development in Mice

  2021cites this paper
• Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review.

  2021cites this paper
• BMP antagonists in tissue development and disease

  2021cites this paper
• Cadmium toxicity: A role in bone cell function and teeth development.

  2021cites this paper
• Effects of sclerostin antibody on bone healing

  2021cites this paper
• Genetics and Genomics of SOST: Functional Analysis of Variants and Genomic Regulation in Osteoblasts

  2021cites this paper
• Detection of chromosomal abnormalities, copy number variations (cnvs), and mutations causing

  2021cites this paper
• Sclerostin and Its Associations With Bone Metabolism Markers and Sex Hormones in Healthy Community-Dwelling Elderly Individuals and Adolescents

  2020cites this paper
• The Effects of Sclerostin on the Immune System

  2020cites this paper
• The Role of Sclerostin in Bone and Ectopic Calcification

  2020cites this paper
• Genetics of Skeletal Disorders.

  2020cites this paper
• Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review.

  2020cites this paper
• Influence of Sost deficiency and skeletal maturation on the bone modeling and remodeling response to mechanical loading

  2020cites this paper
• Looking for new anabolic treatment from rare diseases of bone formation.

  2020influential citation
• Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders

  2020influential citation
• Correlation between bone turnover and metabolic markers with age and gender: a cross-sectional study of hospital information system data

  2020cites this paper
• Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies

  2019cites this paper
• Effects of Long-Term Sclerostin Deficiency on Trabecular Bone Mass and Adaption to Limb Loading Differ in Male and Female Mice

  2019cites this paper
• Romosozumab: a novel bone anabolic treatment option for osteoporosis?

  2019cites this paper
• Targeting WNT signaling in the treatment of osteoporosis.

  2018cites this paper
• High bone mass in adults.

  2018cites this paper
• Anabolic Therapy for the Treatment of Osteoporosis in Childhood

  2018cites this paper
• Human Genetics of Sclerosing Bone Disorders

  2018cites this paper
• Bone: Another potential target to treat, prevent and predict diabetes

  2018cites this paper
• Monoclonal antibodies for treating osteoporosis

  2018cites this paper
• Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.

  2018cites this paper
• The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis

  2018cites this paper
• Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway

  2018cites this paper
• Genetic approaches to metabolic bone diseases

  2018cites this paper
• Les hyperdensités osseuses de l’adulte

  2018cites this paper
• Biology of Bone and Cartilage

  2018cites this paper
• Functional Adaptation of Bone: The Mechanostat and Beyond

  2018cites this paper
• Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.

  2017cites this paper
• Bone Microenvironment and Role of Rank-Rankl-Opg in Breast Cancer Metastasis in Bone

  2017cites this paper
• Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.

  2017cites this paper
• 24-hour profile of serum sclerostin and its association with bone biomarkers in men

  2017cites this paper
• Osteoporosis treatment: recent developments and ongoing challenges.

  2017cites this paper
• Ocular Manifestations of Musculoskeletal Disorders

  2017cites this paper
• Sclerostin measurement in human disease: Validity and current limitations.

  2017cites this paper
• Profile of romosozumab and its potential in the management of osteoporosis

  2017cites this paper
• Physical training, inflammation and bone integrity in elite female rowers

  2017cites this paper
• Is Sclerostin Glycoprotein a Suitable Biomarker for Equine Osteochondrosis?

  2017cites this paper
• Van Buchem disease

  2017cites this paper
• Sclerostin deficiency in humans.

  2017cites this paper
• Clinical utility of anti-sclerostin antibodies.

  2017cites this paper
• TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.

  2017cites this paper
• Genotype-phenotype analysis of a rare type of osteogenesis imperfecta in four Chinese families with WNT1 mutations.

  2016cites this paper
• Effects of the Lyme disease pathogen Borrelia burgdorferi on murine bone biology

  2016cites this paper
• Sclerostin Inhibition in the Management of Osteoporosis

  2016cites this paper
• Circulating Sclerostin in Bone Sclerosing Disorders

  2016cites this paper
• Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts

  2016cites this paper
• From disease to treatment: from rare skeletal disorders to treatments for osteoporosis

  2016cites this paper
• A Novel Domain‐Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone

  2016cites this paper
• Sclerostin and Bone Aging: A Mini-Review

  2016cites this paper
• Variations of SOST mRNA expression in human bone are associated with DNA polymorphism and DNA methylation in the SOST gene.

  2016cites this paper
• Sclerosing bone dysplasias: genetic, clinical and radiology update of hereditary and non-hereditary disorders.

  2016cites this paper
• Sclerostin serum levels in patients with systemic autoimmune diseases.

  2016cites this paper
• Idiopathic Acquired Osteosclerosis in a Middle‐Aged Woman With Systemic Lupus Erythematosus

  2016cites this paper
• Genetic control of bone mass.

  2016cites this paper
• Cytosolic and Endosomal DNA-Sensing Pathways Differentially Regulate Inflammatory Arthritis, Autoantibody Production, and Bone Remodeling: A Dissertation

  2016cites this paper
• Has sclerostin a true endocrine metabolic action complementary to osteocalcin in older men?

  2016cites this paper
• Skeletal Adaptation to Mechanical Strain: A Key Role in Osteoporosis

  2016cites this paper
• Serum Sclerostin as Biomarker in Osteogenesis Imperfecta

  2016cites this paper
• The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6

  2016cites this paper
• Novel therapies for osteoporosis.

  2015cites this paper
• Progressive diaphyseal dysplasia or Camurati-Engelmann disease: diagnostic of the case

  2015cites this paper
• A Multiscale Systems Model for Advancement of a New Line of Therapy for Osteoporosis

  2015cites this paper
• Romosozumab and Blosozumab: Alternative Drugs of Mechanical Strain-Related Stimulus Toward a Cure for Osteoporosis

  2015cites this paper
• New treatments of osteoporosis

  2015cites this paper
• Perspectives on osteoporosis therapies

  2015cites this paper
• A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

  2015cites this paper
• Bone remodeling in the context of cellular and systemic regulation: the role of osteocytes and the nervous system.

  2015cites this paper
• Dickkopf-1 and Sclerostin Serum Levels in Patients with Systemic Mastocytosis

  2015cites this paper
• Decompressive surgery in a patient with hyperostosis corticalis generalisata for relief of cognitive disability and dysaesthesia

  2015cites this paper
• SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.

  2015cites this paper
• Novel targets for the prevention of osteoporosis – lessons learned from studies of metabolic bone disorders

  2015cites this paper
• Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and is not silenced by DNA methylation in osteosarcoma.

  2015cites this paper
• Sclerostin Blood Levels Before and After Kidney Transplantation

  2014cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2014cites this paper
• Antisense oligonucleotide-mediated modulation of SOST and Rank expression

  2014cites this paper
• Sclerosing bone dysplasias with involvement of the craniofacial skeleton.

  2014cites this paper
• The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis

  2014influential citation
• Update on romosozumab: a humanized monoclonal antibody to sclerostin

  2014influential citation
• Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.

  2014cites this paper